National and Kapodistrian University of Athens
Ο ρόλος του πολυμορφισμού του υποδοχέα της καλσιτονίνης στην ανταπόκριση της οστικής πυκνότητας στην θεραπεία με ενδορρινική χορήγηση καλσιτονίνης σολομού σε μετεμμηνοπαυσιακές γυναίκες
Abstract
dc:descriptionOBJECTIVE : In order to assess whether there is an impact of the AluI polymorphism of the calcitonin receptor as well as the BsmI polymorphism of the vitamin D receptor on the response of bone mineral density of postmenopausal women with osteoporosis to the intranasal calcitonin therapy 200IU, we conducted a 1-year, open, prospective study. PATIENTS AND METHODS : A total of one hundred and fifty seven postmenopausal Greek women, aged 51-74 years, were enrolled and received 200IU intranasal intermittent calcitonin and 0,25µg of 1a(OH)vitaminD3 plus 500mg of elemental calcium daily for twelve months. BMD of the lumbar spine and hip (neck and trochanter) were measured by dual energy X-ray absorptiometry (DXA) method, at the beginning and after 12 months of treatment. Genomic DNA was extracted from peripheral blood leukocytes with a DNA extraction kit (Puregene DNA isolation kit, Gentra Systems Inc., Munich, Germany) and PCR was performed using taq DNA polymerase. All women were Caucasian and genetically unrelated. Informed consent was obtained by all participant subjects. The protocol was approved by the Ethics Committee of Athens University. Past history of peripheral and vertebral fractures was recorded. RESULTS : Patients were divided in three subgroups according to the AluI polymorphism of the calcitonin receptor [TT n=73 (46%), TC, n=75 (48%), CC, n=9 (6%)] and three subgroups according to the BsmI polymorphism of the VDR receptor [BB n=42 (26%), Bb n=89 (56%), bb n=28 (18%)]. These results were in accordance to the results of other Caucasian populations. Baseline characteristics of participants, including age, body mass index and calcium intake were similar among groups. Baseline BMD of spine and hip showed no statistical difference among subgroups of polymorphisms although we noticed a lower spine and hip BMD value in bb subgroup and a slightly lower spine BMD in TT subgroup at the beginning of the study. There was an increase in spine BMD in all subgroups of CTR and VDR polymorphisms and an increase in hip BMD of TT and TC subgroups of the CTR polymorphism but these results were not statistically significant. Attempting to analyse the genotype combination of both CTR and VDR polymorphisms, we found that in some subgroups there were very few subjects that could not be analysed (e.g. CC subgroup) and in some combinations there were no patients. So, we analysed CC and TC subgroups together. We noticed lower spine and hip BMD values in bb+TT combination but with no statistical difference from other combinations. There was no statistical increase in BMD values in any genotype combination during the study. During the analysis of the preexisting vertebral and peripheral fractures, we noticed higher incidence of vertebral fractures in bb genotype and peripheral fractures in TT genotype, but none of these were statistically significant, perhaps due to the small number of subjects. During the study, no fractures were reported. CONCLUSION: All patients with different calcitonin and vitamin D receptor gene polymorphisms (AluI and BsmI) can benefit from the therapy with calcitonin. No subgroup showed statistical increase of the spine and hip BMD during the calcitonin therapy. Large numbers of patients are needed in order to show whether there is an impact of calcitonin therapy according to the CTR and VDR polymorphisms.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Katsalira, Aikaterini
- Κατσαλήρα, Αικατερίνη
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24237